A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Launched by VIVACELLE BIO · Oct 2, 2023

Keywords

ClinConnect Summary

This clinical trial, called VBI-S-02, is investigating a new treatment called VBI-S for patients suffering from septic shock, a serious condition caused by infections that can lead to dangerously low blood pressure and organ failure. The goal of the study is to see if VBI-S can safely help raise blood pressure in patients who have not responded well to standard fluid treatments. The trial is currently looking for participants aged 18 and older who have clear signs of infection and very low blood pressure that isn't improving with regular fluids.

To be eligible for this study, patients should have a confirmed bacterial infection and a specific blood pressure reading that indicates they need additional support. The study is open to all genders, and participants will receive VBI-S to see how well it works compared to existing treatments. It’s important to note that patients with certain health conditions, such as severe heart issues or those who are pregnant, cannot participate. If you or a family member are interested in this trial, it could be a potential opportunity to receive new therapy while contributing to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female at least 18 years of age.
• • 2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
• • 3. Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market.
• • 4. Sequential Organ Failure Assessment (SOFA) score ≥ 5
• 5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
• • Lactate \> 2 mmol/L
• • Fever \> 38.3°C, or 101°F
• • Hypothermia \< 36°C core temperature (\<96.8°F)
• • Heart rate \> 90
• • Tachypnea (respiratory rate ≥ 20/min)
• • White blood cell count \>12,000 or less than 4,000, or with \>10% "bands" (immature forms)
• • Elevated procalcitonin in serum (≥ 2ng/ml)
• • Arterial hypoxemia (PaO2/FiO2 \< 300)
• • Creatinine increase \> 0.5 mg/dL since hospital admission
• • INR \> 1.5 or aPTT \> 60 seconds
• • 6. Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
• • 7. Receiving vasopressors to maintain the target MAP of 65 mmHg.
• Exclusion Criteria:
• • 1. Patients with a ventricular assist device
• • 2. Acute coronary syndrome
• • 3. Pregnant
• • 4. Acute bronchospasm
• • 5. Acute Mesenteric ischemia
• • 6. Emergency major surgery
• • 7. Diagnosis of acute Hepatitis B or C.
• • 8. Hematologic or coagulation disorders including thrombocytopenia (platelet count \<50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.
• • 9. White blood cell count of \< 1000 mm3
• • 10. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.
• • 11. Patients with a known allergy to soybeans or eggs
• • 12. Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.
• • 13. Patient expected to expire within 12 hours.
• • 14. Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.